Report of Foreign Issuer (6-k)
April 27 2020 - 4:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of
April 2020
Commission File Number: 001-31368
SANOFI
(Translation of
registrants name into English)
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F
or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule
101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
☐
No ☒
If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In April 2020, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are
incorporated herein by reference.
Exhibit List
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated April 24, 2020: Sanofi at forefront of fight against COVID-19 in Q1 2020
|
|
|
Exhibit 99.2
|
|
Press release dated April 24, 2020: FDA approves MenQuadfiTM the latest innovation in meningococcal (MenACWY) vaccination
|
|
|
Exhibit 99.3
|
|
Press release dated April 23, 2020: Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
|
2
Exhibit Index
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated April 24, 2020: Sanofi at forefront of fight against COVID-19 in Q1 2020
|
|
|
Exhibit 99.2
|
|
Press release dated April 24, 2020: FDA approves MenQuadfiTM the latest innovation in meningococcal (MenACWY) vaccination
|
|
|
Exhibit 99.3
|
|
Press release dated April 23, 2020: Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Dated: April 27, 2020
|
|
|
|
|
|
SANOFI
|
|
|
|
|
|
|
|
|
By
|
|
/s/ Alexandra Roger
|
|
|
|
|
|
|
Name: Alexandra Roger
|
|
|
|
|
|
|
Title: Head of Securities Law and
Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Apr 2023 to Apr 2024